Insulet Corporation

PODD Healthcare Medical - Devices NASDAQ

PDF Back to Search

$272.14

+$0.54 (+0.20%)

Open: $271.56 | High: $275.92 | Low: $270.11 | Prev Close: $271.60

Market Cap: $19.14B

Volume: 328K | Avg: 726K

Last updated: January 26, 2026 at 06:04 PM
Featured In

This stock appears in the following dashboards:

Options Activity
Featured
Options Screener
Featured
Options Activity for PODD
Options Screener Data
Type Strike Expiration Premium Premium Yield Call Vol Put Vol P/C Ratio Rating
N/A $N/A N/A $N/A N/A% N/A N/A N/A N/A/10
View Full Options Screener
Puts/Calls Activity
Type Strike Expiration Premium Volume ROI % Breakeven Delta
N/A $N/A N/A $N/A N/A N/A% $N/A N/A
View Full Options Activity
Investment Rating
C+

Sell

Overall Score: 40/100

Rating Breakdown:
DCF Score 1/5
20%
Strong Sell
ROE Score 4/5
80%
Buy
ROA Score 4/5
80%
Buy
D/E Score 1/5
20%
Strong Sell
P/E Score 1/5
20%
Strong Sell
P/B Score 1/5
20%
Strong Sell
Add to Watchlist Add to Portfolio
Stock Score Analysis
D

Stock Score: 565

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 30
Financial Health 95
Growth 100
Market Sentiment 0
Risk 40
Lower is better
Valuation 0
Momentum 0
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 79.57
P/B Ratio 13.89
P/S Ratio 7.59
EPS $3.42
Beta 1.40
Shares Outstanding 70.35M
Price Range & Moving Averages
52-Week High $354.88
52-Week Low $230.05
SMA 50 $301.32
SMA 200 $304.71
Earnings
Next Earnings February 18, 2026 01:30 PM ET
Financial Ratios
Margins
Gross Margin 71.5%
Operating Margin 17.3%
Net Margin 9.8%
Returns
ROE 18.3%
ROA 8.1%
Liquidity & Leverage
Debt/Equity 0.75
Current Ratio 2.87
Quick Ratio 2.18
Balance Sheet
Total Assets $3.09B
Total Liabilities $1.88B
Total Equity $1.21B
Cash $953.40M
Total Debt $1.42B
Net Debt $468.60M
Income Statement
Revenue $2.07B
Gross Profit $1.45B
Operating Income $308.90M
Net Income $418.30M
EBITDA $423.70M
Revenue/Share $35.70
Cash Flow
Operating CF $430.30M
CapEx $124.90M
Free Cash Flow $305.40M
Book Value/Share $19.59
Tangible Book/Share $17.38
Equity/Share $19.59
Technical Indicators
RSI (14) 50.00 Neutral
MACD
0.00 Signal: 0.00
Volatility 0.00%
Trading Signal Neutral
Performance & Returns

Insufficient historical data

Insufficient historical data (need 200+ days, have 0)
Sector Comparison (Healthcare)
Compared to 45 peers in Healthcare
Metric PODD Sector Avg Percentile
P/E Ratio 79.57 34.26 91%
P/B Ratio 13.89 -0.04 91%
ROE (%) 18.27% 14.08% 57%
Net Margin (%) 9.76% 9.65% 39%
Stock Score 565 466.0 91%
Percentile: 0% = worst in sector, 100% = best in sector
Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
PODD $272.14 $0.00 $0.00 $0.00 $0.00 $0.00 50.00 0.00 0.00% 0 Neutral Mixed
Candlestick Patterns

There wasn't any recognizable pattern for the PODD stock

News Sentiment
📊 Ticker 📰 Headline 💭 Sentiment 📡 Source 🔗 URL
PODD Here's Why Insulet (PODD) is a Strong Growth Stock Positive zacks.com Read More
PODD Inscription Capital LLC Takes $1.01 Million Position in Insulet Corporation $PODD Neutral defenseworld.net Read More
PODD Is Insulet (PODD) the Future of Diabetes Management? Neutral fool.com Read More
PODD Is PODD A Better Bet Than ISRG Stock? Neutral forbes.com Read More
PODD Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Neutral seekingalpha.com Read More
Recent Insider Trading
Date Insider Position Transaction Shares Price Value
2026-01-02 Cousin Laetitia officer: SVP, Reg, Quality & Compliance SELL 140 $282.92 $39609
2025-12-31 Huffines Robert Luther director BUY 50 $284.24 $14443
2025-12-15 Frederick Wayne A.I. director SELL 1851 $293.09 $542510
2025-12-05 STONESIFER TIMOTHY C. director BUY 962 $311.73 $299884
Showing last 10 insider transactions. Green badges indicate purchases (bullish signal), red badges indicate sales.
Company Information

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

CEO Ashley A. McEvoy
Employees 3900
Country US
IPO Date 2007-05-15
Exchange NASDAQ
Website https://www.insulet.com
Sector Healthcare
Industry Medical - Devices
Similar Stocks (Healthcare - Medical - Devices)
ABT

Abbott Laboratories

Price: $108.43
Change: +0.94%
Market Cap: $1887B
P/E: 29.15
Score: E (510)
View Details
BSX

Boston Scientific Corporation

Price: $93.74
Change: +1.33%
Market Cap: $1390B
P/E: 50.13
Score: E (520)
View Details
SYK

Stryker Corporation

Price: $357.20
Change: +0.61%
Market Cap: $1366B
P/E: 47.00
Score: E (520)
View Details
EW

Edwards Lifesciences Corporation

Price: $84.12
Change: +0.56%
Market Cap: $4938B
P/E: 36.89
Score: D (545)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.